KRAS and malignant colon neoplasm: Since the CMS1–MSI-immune colon cancer subtype is also characterized by high MSI, high levels of BRAF mutations, and low levels KRAS mutations, we decided to explore whether CD68High tumors presented differences in HIF1A expression comparing MSI/MSS, and BRAF and KRAS wild-type versus mutated.